Payment overview · 2025
General Payments
$541.80
26 reported records · 17 companies
Healthcare provider profile · identity verified
Kamran Qureshi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HEMET, CA · NPI 1326156472
Verified facts
What the public records show
CMS Open Payments records show Kamran Qureshi, M.D. received $541.80 in general payments during 2025 across 26 reported records.
Lilly USA, LLC accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.76 | 14.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.75 | 9.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.75 | 9.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.78 | 7.9% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $42.49 | 7.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.83 | 7.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.29 | 6.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.33 | 5.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $24.85 | 4.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.41 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.18 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.71 | 4.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.04 | 3.3% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.02 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.83 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.94 | 2.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.84 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $541.80 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.08 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.75 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.78 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 766 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 738 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 164 |
| Lisinopril | Lisinopril | 598 | 128 |
| Losartan Potassium | Losartan Potassium | 501 | 109 |
| Gabapentin | Gabapentin | 434 | 111 |
| Metformin Hcl | Metformin Hcl | 432 | 102 |
| Simvastatin | Simvastatin | 348 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 84 |
| Omeprazole | Omeprazole | 325 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 254 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 44 |
| Carvedilol | Carvedilol | 202 | 46 |
| Furosemide | Furosemide | 197 | 52 |
| Trazodone Hcl | Trazodone Hcl | 178 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 35 |
| Sertraline Hcl | Sertraline Hcl | 159 | 30 |
| Eliquis | Apixaban | 136 | 34 |
| Montelukast Sodium | Montelukast Sodium | 123 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 37 |
| Alprazolam | Alprazolam | 121 | 34 |
| Famotidine | Famotidine | 121 | 31 |
| Potassium Chloride | Potassium Chloride | 121 | 34 |
| Azithromycin | Azithromycin | 120 | 87 |
| Atenolol | Atenolol | 118 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 96 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 19 |
| Glimepiride | Glimepiride | 89 | 23 |
| Estradiol | Estradiol | 86 | 21 |
| Glipizide | Glipizide | 86 | 20 |
| Prednisone | Prednisone | 86 | 37 |
| Synthroid | Levothyroxine Sodium | 82 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 36 |
| Alendronate Sodium | Alendronate Sodium | 75 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 18 |
| Propranolol Hcl | Propranolol Hcl | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 15 |
| Ibuprofen | Ibuprofen | 71 | 23 |
| Meloxicam | Meloxicam | 71 | 29 |
| Ozempic | Semaglutide | 71 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 14 |
| Benazepril Hcl | Benazepril Hcl | 69 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 15 |
| Allopurinol | Allopurinol | 67 | 12 |
| Tramadol Hcl | Tramadol Hcl | 65 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 13 |
| Acyclovir | Acyclovir | 64 | 17 |
| Lovastatin | Lovastatin | 62 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Enalapril Maleate | Enalapril Maleate | 60 | 16 |
| Finasteride | Finasteride | 60 | 15 |
| Jardiance | Empagliflozin | 60 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 13 |
| Clonidine Hcl | Clonidine Hcl | 52 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 19 |
| Buspirone Hcl | Buspirone Hcl | 48 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Baclofen | Baclofen | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 33 |
| Terazosin Hcl | Terazosin Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | 12 |
| Valsartan | Valsartan | 41 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 19 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Cephalexin | Cephalexin | 26 | 15 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Nystatin | Nystatin | 25 | 13 |
| Azelastine Hcl | Azelastine Hcl | 24 | 14 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 14 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 14 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | 12 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $541.80 · 26 records | Lilly USA, LLC | AREXVY, BREZTRI, Cologuard Collection Kit, DAXXIFY, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JATENZO, Leqembi, MOUNJARO, NEXLETOL, NP Thyroid 60, OTEZLA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error